Cargando…

Getting to the “Heart” of the Matter on Diabetic Cardiovascular Disease: “Thanks for the Memory”

Detalles Bibliográficos
Autores principales:	Cefalu, William T., Rosenstock, Julio, LeRoith, Derek, Blonde, Lawrence, Riddle, Matthew C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2016
Materias:	Cardiovascular Disease and Diabetes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013718/ https://www.ncbi.nlm.nih.gov/pubmed/27208373 http://dx.doi.org/10.2337/dc16-0405

Ejemplares similares

Insulin’s Role in Diabetes Management: After 90 Years, Still Considered the Essential “Black Dress”
por: Cefalu, William T., et al.
Publicado: (2015)

Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management: Reflections From a Diabetes Care Editors’ Expert Forum
por: Cefalu, William T., et al.
Publicado: (2014)

Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors’ Expert Forum
por: Raz, Itamar, et al.
Publicado: (2013)

Epidemiology and Molecular Mechanisms Tying Obesity, Diabetes, and the Metabolic Syndrome With Cancer
por: Gallagher, Emily J., et al.
Publicado: (2013)

Status of Diabetes Care: “It Just Doesn’t Get Any Better . . . or Does It?”
por: Cefalu, William T., et al.
Publicado: (2014)

Is Hyperglycemia a Causal Factor in Cardiovascular Disease?: Does proving this relationship really matter? Yes
por: Davidson, Jaime A., et al.
Publicado: (2009)

The Role of Insulin and Insulin-like Growth Factors in the Increased Risk of Cancer in Diabetes
por: LeRoith, Derek, et al.
Publicado: (2011)

Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011)

Glucose Control and Cardiovascular Disease: Is it important? No
por: Conget, Ignacio, et al.
Publicado: (2009)

Is Hyperglycemia a Cardiovascular Risk Factor?
por: Pistrosch, Frank, et al.
Publicado: (2011)

Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease
por: Versari, Daniele, et al.
Publicado: (2009)

Heart in Diabetes: A Microvascular Disease
por: Laakso, Markku
Publicado: (2011)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
por: Kassem, Sameer A., et al.
Publicado: (2009)

Heart in Diabetes: Not Only a Macrovascular Disease
por: Stratmann, Bernd, et al.
Publicado: (2011)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
por: Bianchi, Cristina, et al.
Publicado: (2009)

Diabetes Care: “Lagniappe” and “Seeing Is Believing”!
por: Cefalu, William T., et al.
Publicado: (2016)

Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study
por: Gori, Mauro, et al.
Publicado: (2016)

Status of Diabetes Care: New Challenges, New Concepts, New Measures—Focusing on the Future!
por: Cefalu, William T., et al.
Publicado: (2015)

The Munich Myocardial Infarction Registry: Translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice
por: Schnell, Oliver, et al.
Publicado: (2009)

Should C-Reactive Protein Be a Target of Therapy?
por: Oh, Jisun, et al.
Publicado: (2011)

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum
por: Cefalu, William T., et al.
Publicado: (2018)

Building Momentum: Taking on the Real “Issues” of Diabetes Care!
por: Cefalu, William T., et al.
Publicado: (2016)

Diabetes Care: “Taking It to the Limit One More Time”
por: Cefalu, William T., et al.
Publicado: (2017)

Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance
por: Cefalu, William T., et al.
Publicado: (2013)

Hallmarks of cancer: The insulin-like growth factors perspective
por: Werner, Haim, et al.
Publicado: (2022)

Shifting the Disease Management Paradigm From Glucose: What are the pros?
por: Stirban, Alin, et al.
Publicado: (2009)

A Summary of the ADVANCE Trial
por: Heller, Simon R.
Publicado: (2009)

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines
por: Gallwitz, Baptist
Publicado: (2009)

Shifting the Disease Management Paradigm From Glucose: What are the cons?
por: Hanefeld, Markolf, et al.
Publicado: (2009)

Postprandial Hyperglycemia and Glycemic Variability: Should we care?
por: Standl, Eberhard, et al.
Publicado: (2011)

Antiplatelet Therapy for Every Diabetic Person?
por: Nicolucci, Antonio, et al.
Publicado: (2011)

Thanks for the memory
por: Siegel-Itzkovich, J
Publicado: (2003)

Coronavirus and cardiovascular manifestations- getting to the heart of the matter
por: Bhandari, Monika, et al.
Publicado: (2021)

Response to Comment on: Riddle et al. Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes. Diabetes Care 2011;34:2508–2514
por: Riddle, Matthew, et al.
Publicado: (2012)

Connections for Matters of the Heart: Network Medicine in Cardiovascular Diseases
por: Sonawane, Abhijeet Rajendra, et al.
Publicado: (2022)

Get Moving! Your Brain Will Thank You.
por: Nunez, Christina, et al.
Publicado: (2021)

Cardiovascular mortality trends in Switzerland 1995–2018
por: Sorrentino, Lisa, et al.
Publicado: (2022)

The Intricate Role of Growth Hormone in Metabolism
por: Vijayakumar, Archana, et al.
Publicado: (2011)

Editorial: What's New in Endocrinology?
por: Holly, Jeff M. P., et al.
Publicado: (2019)

Serum magnesium and risk of incident heart failure in older men: The British Regional Heart Study
por: Wannamethee, Sasiwarang Goya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8ee4frg6ildllls2b7kui13tlk